Search / Trial NCT06234878

REEV SENSE for Gait Analysis in Post-stroke Gait Impairment (SENS-AG)

Launched by REEV LLC · Jan 22, 2024

Trial Information

Current as of October 04, 2024

Recruiting

Keywords

Stroke Gait Analysis Accelerometer Gait Impairment

Description

REEV SENSE is a medical device, with pending FDA and CE certifications in class 1. It is a connected gait tracker set primarily on the leg or foot, and eventually on lower limb locations. It contains an accelerometer, a certified standard battery and motion analysis algorithms that will rapidly compute easy-to-use walking analyses accessible to healthcare professionals on a mobile app. Standard gait biomarkers such as velocity, stride length, or stance and swing times will be computed. However, REEV has also developed a new biomarker, the knee position predictor (KPP), which will provide a...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Post-stroke gait disorder.
  • * Must be able to walk independently with or without the support of a cane or rollator.
  • * History of stroke more than six months ago.
  • * Be 18 years of age or older.
  • Exclusion Criteria:
  • * Subject unable to give consent.
  • * Subject unable to understand the tests.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Cambridge, Massachusetts, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0